Abstract

Despite knowing that females are at a higher risk of major adverse cardiac events (MACE) and poor prognosis after percutaneous transluminal coronary angioplasty (PTCA), there are very few studies focusing on urinary 11-dehyrdo-thromboxane B2 (dh-TxB2) concentration (for aspirin non-responsiveness) differences among males and females. The present prospective observational study aimed to evaluate the dh-TxB2 levels and associate them with clinical outcomes in males and females with acute coronary syndrome (ACS) after PTCA. The dh-TxB2 ELISA assay was carried out twice, at baseline and 6 months follow-up, and outcomes were assessed for 1 year. The average cut-off value of dh-TxB2 was ≥1,496 pg/mg creatinine by the receiver operating characteristic curve estimation. A total of 192 patients (140 men and 52 women) were enrolled. At baseline, 17 (12.1%) males and 7 (13.5%) females had high dh-TxB2 levels, whereas at 6 months, 22 (15.9%) males and 4 (7.8%) females showed high dh-TxB2 levels. The concentration of dh-TxB2 was higher in females than males at baseline. Composite MACE was not different between genders significantly even when the dh-TxB2 levels were high. Women experienced higher MACE incidences than men (13.5% vs. 9.3%).

Key words: Major adverse cardiac events, Cardiac death, Aspirin, Percutaneous transluminal coronary angioplasty, ELISA assay